The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.
 
Hope S. Rugo
Consulting or Advisory Role - Celltrion; Ionis Pharmaceuticals
Research Funding - Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Daiichi Sankyo; Macrogenics; Merck; Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology
 
Florence Lerebours
No Relationships to Disclose
 
Eva Ciruelos
Honoraria - Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Speakers' Bureau - Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Pamela Drullinsky
Research Funding - Novartis (Inst); Roche (Inst)
 
Manuel Ruiz Borrego
Honoraria - Roche/Genentech
Consulting or Advisory Role - Roche
 
Patrick Neven
Consulting or Advisory Role - Ipsen (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche
 
Yeon Hee Park
Honoraria - AstraZeneca
Consulting or Advisory Role - Pfizer
Speakers' Bureau - Merck
Research Funding - AstraZeneca; Eisai; Novartis; Pfizer
Expert Testimony - Merck
 
Aleix Prat
Employment - Novartis (I)
Honoraria - Amgen; Daiichi Sankyo; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Thomas Bachelot
Consulting or Advisory Role - AstraZeneca; MSD Oncology; Novartis; Pfizer; Roche; Seagen
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; pfizer; Roche
 
Dejan Juric
Consulting or Advisory Role - Eisai; EMD Serono; Genentech; Ipsen; Novartis
 
Nicholas C. Turner
Consulting or Advisory Role - AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Repare Therapeutics; Roche; Taiho Pharmaceutical; Taiho Pharmaceutical; Zeno pharmaceuticals
Research Funding - AstraZeneca (Inst); Bio-Rad (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Pfizer (Inst); Roche (Inst)
 
Nickolas Sophos
Employment - Novartis
 
Juan Pablo Zarate
Employment - Johnson & Johnson (I); Novartis
Stock and Other Ownership Interests - Novartis
 
Christina Arce
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Yu-Ming Shen
No Relationships to Disclose
 
Stephen K. L. Chia
Honoraria - AstraZeneca; Genomic Health; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Genomic Health (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)